Saturday, July 25, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2041

Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.

Patents
151

Quick answer

151 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10888558

    Regimens of tafenoquine for prevention of malaria in malaria-naive subjects

    The Government of the United States, as represented by the Secretary of the Army · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10888619

    Stable aqueous etanercept composition

    Coherus BioSciences, Inc. · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10888516

    Soluble estradiol capsule for vaginal insertion

    Compass Therapeutics LLC · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10888601

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10894053

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10898575

    Long-acting polymeric delivery systems

    Heron Therapeutics, Inc. · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10898551

    Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    HALOZYME, INC. · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10905690

    Treatment of congenital adrenal hyperplasia

    Neurocrine Biosciences, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10905693

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10912771

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10912754

    Methods and compositions for treating excessive sleepiness

    Jazz Pharmaceuticals Ireland Limited · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10912751

    Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

    Esperion Therapeutics, Inc. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10918722

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10933137

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10933076

    Crocin-sorafenib combination therapy for liver cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10933136

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10940133

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    Jazz Pharmaceuticals Ireland Limited · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10940142

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10940141

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10940153

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10946101

    Surfactant-free water-free foamable compositions, breakable foams and gels and their uses

    Vyne Therapeutics Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10947306

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10945988

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10952997

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10954293

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10954295

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10953003

    Methods for treating cancer

    X4 Pharmaceuticals, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10953018

    Emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10953000

    Combination of pimavanserin and cytochrome P450 modulators

    ACADIA Pharmaceuticals Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10954294

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10959976

    Methods and compositions for treating excessive sleepiness

    Jazz Pharmaceuticals Ireland Limited · Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10975138

    Correctly folded etanercept composition

    Coherus BioSciences, Inc. · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10973758

    Methods of eye treatment using therapeutic compositions containing dipyridamole

    O.D. Ocular Discovery Ltd. · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10973879

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10980885

    Method of reducing formation of etanercept aggregates or fragments

    Coherus BioSciences, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10980884

    Stable aqueous etanercept composition

    Coherus BioSciences, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10980770

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10980788

    Therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10980886

    Compositions of a polyorthoester and an organic acid excipient

    Heron Therapeutics, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10987405

    Method of reducing formation of etanercept aggregates or fragments

    Coherus BioSciences, Inc. · Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10987346

    Iloperidone for the treatment of schizophrenia

    VANDA PHARMACEUTICALS INC. · Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10987358

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10988778

    Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10993941

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11001627

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11000517

    Dosage and formulation

    Almirall, S.A. · Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11000502

    Antimicrobial compositions comprising copper-hydroxypyrone complexes

    United Kingdom Research and Innovation · Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11001578

    N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2041?

151 published patents in our USPTO index have expiration dates falling in calendar year 2041.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.